SHINE Technologies and Von Gahlen International today announced that SHINE’s supercell has passed factory acceptance testing. Completion of that testing means the supercell, a bank of 10 hot cells, is now being prepared for final shipment to The Chrysalis, SHINE’s large-scale medical isotope production facility in Janesville, Wisconsin.
The supercell will house key processes of medical isotope production, including the extraction, purification and packaging of molybdenum-99 (Mo-99). The medical isotope is relied on for more than 40 million patient procedures per year globally, and the supercell will play a vital role in SHINE’s ability to produce up to 20 million doses of Mo-99 each year. Von Gahlen was awarded the contract for the supercell based on its expertise in manufacturing critical solutions for nuclear medicine and radiopharmacy, commitment to the SHINE project, and its alignment with SHINE’s core values.
“We’re thankful to have been chosen to partner on this project and cherished the challenge of producing something so unique,” said Jaap Duiker, Managing Director from Von Gahlen. “To know that this work could help up to 20 million patients potentially facing cancer or heart disease makes this project particularly special. We look forward to continuing to work with SHINE and share in their vision for a safer, healthier, and cleaner world.”
;
